Related references
Note: Only part of the references are listed.Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy
Keishi Adachi et al.
CANCER SCIENCE (2015)
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
Dalil Hannani et al.
CELL RESEARCH (2015)
Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer
Chee-Seng Tan et al.
LANCET ONCOLOGY (2015)
AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Overcoming Resistance to Targeted Therapies in Cancer
Keara L. Redmond et al.
SEMINARS IN ONCOLOGY (2015)
The IL-2 cytokine family in cancer immunotherapy
Geok Choo Sim et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2014)
Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy
Denise Skrombolas et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2014)
IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients
Geok Choo Sim et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
IL-2: The First Effective Immunotherapy for Human Cancer
Steven A. Rosenberg
JOURNAL OF IMMUNOLOGY (2014)
Retrospective Analysis of the Safety and Efficacy of High-dose Interleukin-2 After Prior Tyrosine Kinase Inhibitor Therapy in Patients With Advanced Renal Cell Carcinoma
Elaine T. Lam et al.
JOURNAL OF IMMUNOTHERAPY (2014)
Immune Checkpoint Blockade: The Hope for Immunotherapy as a Treatment of Lung Cancer?
Julie R. Brahmer
SEMINARS IN ONCOLOGY (2014)
Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy
Melissa Bersanelli et al.
CANCERS (2014)
Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy
Wei Liao et al.
IMMUNITY (2013)
Immunocytokines: a review of molecules in clinical development for cancer therapy
Thomas List et al.
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS (2013)
Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer
Xin Yao et al.
BLOOD (2012)
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'
Aron M. Levin et al.
NATURE (2012)
Adoptive immunotherapy for cancer: harnessing the T cell response
Nicholas P. Restifo et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases
John Puskas et al.
IMMUNOLOGY (2011)
Endothelial Nitric Oxide Synthase Is a Key Mediator of Interleukin-2-Induced Hypotension and Vascular Leak Syndrome
Wolfram E. Samlowski et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Off-Target Serine/Threonine Kinase 10 Inhibition by Erlotinib Enhances Lymphocytic Activity Leading to Severe Skin Disorders
Naoko Yamamoto et al.
MOLECULAR PHARMACOLOGY (2011)
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Douglas J. Schwartzentruber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Th17 and Regulatory T Cells in Mediating and Restraining Inflammation
Dan R. Littman et al.
CELL (2010)
MART-1-Specific Melanoma Tumor-Infiltrating Lymphocytes Maintaining CD28 Expression Have Improved Survival and Expansion Capability Following Antigenic Restimulation In Vitro
Yufeng Li et al.
JOURNAL OF IMMUNOLOGY (2010)
Increase of Circulating CD4+CD25highFoxp3+ Regulatory T Cells in Patients With Metastatic Renal Cell Carcinoma During Treatment With Dendritic Cell Vaccination and Low-Dose Interleukin-2
Annika Berntsen et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells
Carsten Krieg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
How are TH2-type immune responses initiated and amplified?
William E. Paul et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Structural Biology of Shared Cytokine Receptors
Xinquan Wang et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2
Christoph Schliemann et al.
BLOOD (2009)
IL-1β and IL-2 convert human Treg into TH17 cells
Florence Deknuydt et al.
CLINICAL IMMUNOLOGY (2009)
Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression
Ethan M. Shevach
IMMUNITY (2009)
The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer
Karola Wagner et al.
CLINICAL CANCER RESEARCH (2008)
Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines
Franz O. Smith et al.
CLINICAL CANCER RESEARCH (2008)
Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group
Michael B. Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
Mark E. Dudley et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Steven A. Rosenberg et al.
NATURE REVIEWS CANCER (2008)
Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: A meta-analysis of 18 trials involving 2,621 patients
Natalie J. Ives et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer
Kim Margolin et al.
CLINICAL CANCER RESEARCH (2007)
Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak
Diana C. Gallagher et al.
CLINICAL CANCER RESEARCH (2007)
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma
A. D. Sasse et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2007)
Both integrated and differential regulation of components of the IL-2/IL-2 receptor system
Hyoung Pyo Kim et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2006)
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma
E Bajetta et al.
ANNALS OF ONCOLOGY (2006)
Cytokine-based therapy and biochemotherapy for advanced melanoma
MB Atkins
CLINICAL CANCER RESEARCH (2006)
Phenotypic and functional characterization of human CD25+ B cells
M Brisslert et al.
IMMUNOLOGY (2006)
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: A study of the Children's Oncology Group
KL Osenga et al.
CLINICAL CANCER RESEARCH (2006)
IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients
M Ahmadzadeh et al.
BLOOD (2006)
Antibody targeted drugs as cancer therapeutics
D Schrama et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study
AV Maker et al.
ANNALS OF SURGICAL ONCOLOGY (2005)
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: A randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group
U Keilholz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The structure of interleukin-2 complexed with its alpha receptor
M Rickert et al.
SCIENCE (2005)
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
ME Dudley et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
DF McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2) - Results of a phase 1 trial in patients with prostate cancer
YJ Ko et al.
JOURNAL OF IMMUNOTHERAPY (2004)
Preferential activation of an IL-2 regulatory sequence transgene in TCRγδ and NKT cells:: Subset-specific differences in IL-2 regulation
MA Yui et al.
JOURNAL OF IMMUNOLOGY (2004)
NK cells and polymorphonuclear neutrophils are both critical for IL-2-induced pulmonary vascular leak syndrome
E Assier et al.
JOURNAL OF IMMUNOLOGY (2004)
Modulation of multidrug resistance-associated protein 2 (Mrp2) and Mrp3 expression and function with small interfering RNA in sandwich-cultured rat hepatocytes
XB Tian et al.
MOLECULAR PHARMACOLOGY (2004)
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer
JC Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Interleukin-2 mutants with enhanced alpha-receptor subunit binding affinity
BM Rao et al.
PROTEIN ENGINEERING (2003)
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial
O Eton et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon α-2b in advanced renal cell carcinoma:: major durable responses in a less highly selected patient population
JI Clark et al.
ANNALS OF ONCOLOGY (2002)
Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alfa-2b in advanced melanoma outpatients: Results from an Italian Multicenter phase III Randomized Clinical Trial
R Ridolfi et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix
B Carnemolla et al.
BLOOD (2002)
Cytokines and immunodeficiency diseases
WJ Leonard
NATURE REVIEWS IMMUNOLOGY (2001)
A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo
AB Shanafelt et al.
NATURE BIOTECHNOLOGY (2000)
Share Paper
